Colchicine and Cardiovascular Disease: Mechanisms, Clinical Evidence, and Therapeutic Perspectives

Zhiyang Lv; Xiaodi Chen; Qing Lu; Shifang Ding

doi:10.26689/cr.v3i3.12333

Zhiyang Lv Department of Cardiology, Yichang Central People’s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang 443003, Hubei, China
Xiaodi Chen Department of Ultrasound, Yichang Central People’s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang 443003, Hubei, China
Qing Lu Department of Cardiology, General Hospital of Central Theater Command, Wuhan Clinical Medicine College of Southern Medical University, Wuhan, 430070, Hubei, China
Shifang Ding Department of Cardiology, General Hospital of Central Theater Command, Wuhan Clinical Medicine College of Southern Medical University, Wuhan, 430070, Hubei, China

DOI: https://doi.org/10.26689/cr.v3i3.12333

Keywords: Colchicine, Cardiovascular disease, Inflammation

Abstract

Colchicine, a long-established anti-inflammatory agent, has recently drawn growing interest due to its possible therapeutic roles in cardiovascular disorders. By modulating inflammatory pathways, colchicine has been shown to enhance clinical outcomes in patients with pericarditis, coronary artery involvement, as well as postoperative atrial fibrillation, and to lower the risk of recurrent cardiovascular events. Nevertheless, its underlying pharmacological mechanisms and sustained benefits still warrant comprehensive evaluation. This review summarizes current understanding of colchicine’s mechanisms, clinical evidence, and prospective applications, offering updated perspectives for its use in cardiovascular medicine.

References

Nerlekar N, Beale A, Harper R, 2014, Colchicine – A Short History of an Ancient Drug. Med J Aust, 201(11): 687–688.

Dasgeb B, Kornreich D, Mcguinn K, et al., 2018, Colchicine: An Ancient Drug With Novel Applications. Br J Dermatol, 178(2): 350–356.

Niel E, Scherrmann J, 2006, Colchicine Today. Joint Bone Spine, 73(6): 672–678.

Dixon D, Patel J, Spence R, et al., 2022, Select Drug–Drug Interactions With Colchicine and Cardiovascular Medications: A Review. Am Heart J, 252: 42–50.

Akodad M, Sicard P, Fauconnier J, et al., 2020, Colchicine and Myocardial Infarction: A Review. Arch Cardiovasc Dis, 113(10): 652–659.

Reyes A, Hu K, Teperman J, et al., 2021, Anti-Inflammatory Therapy for COVID-19 Infection: The Case for Colchicine. Ann Rheum Dis, 80(5): 550–557.

Siak J, Flint N, Shmueli H, et al., 2021, The Use of Colchicine in Cardiovascular Diseases: A Systematic Review. Am J Med, 134(6): 735–744.e1.

Guan T, Gao B, Chen G, et al., 2013, Colchicine Attenuates Renal Injury in a Model of Hypertensive Chronic Kidney Disease. Am J Physiol Renal Physiol, 305(10): F1466–F1476.

Entzian P, Schlaak M, Seitzer U, et al., 1997, Antiinflammatory and Antifibrotic Properties of Colchicine: Implications for Idiopathic Pulmonary Fibrosis. Lung, 175(1): 41–51.

Wu Q, Liu H, Liao J, et al., 2020, Colchicine Prevents Atrial Fibrillation Promotion by Inhibiting IL-1β-Induced IL-6 Release and Atrial Fibrosis in the Rat Sterile Pericarditis Model. Biomed Pharmacother, 129: 110384.

Lv Z, Chen X, Chen P, et al., 2022, Colchicine Prevents Ventricular Arrhythmias Vulnerability in Diet-Induced Obesity Rats. Biochemical and Biophysical Research Communications, 610: 127–132.

Cavallero C, Turolla E, Ricevuti G, 1971, Cell Proliferation in the Atherosclerotic Plaques of Cholesterol-Fed Rabbits. 1. Colchicine and (3H)Thymidine Studies. Atherosclerosis, 13(1): 9–20.

Rodríguez A, Guindo J, Martí V, et al., 1987, Colchicine for Recurrent Pericarditis. Lancet, 2(8574): 1517.

Imazio M, Brucato A, Cemin R, et al., 2013, A Randomized Trial of Colchicine for Acute Pericarditis. N Engl J Med, 369(16): 1522–1528.

Imazio M, Brucato A, Cemin R, et al., 2011, Colchicine for Recurrent Pericarditis (CORP): A Randomized Trial. Ann Intern Med, 155(7): 409–414.

Adler Y, Charron P, Imazio M, et al., 2015, 2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 36(42): 2921–2964.

Imazio M, Brucato A, Ferrazzi P, et al., 2014, Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation: The COPPS-2 Randomized Clinical Trial. JAMA, 312(10): 1016–1023.

Pan T, Jiang C, Zhang H, et al., 2023, The Low-Dose Colchicine in Patients After Non-CABG Cardiac Surgery: A Randomized Controlled Trial. Crit Care, 27(1): 49.

Meurin P, Lelay-Kubas S, Pierre B, et al., 2015, Colchicine for Postoperative Pericardial Effusion: A Multicentre, Double-Blind, Randomised Controlled Trial. Heart, 101(21): 1711–1716.

Kim S, Kim E, Cho J, et al., 2020, Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion. J Am Coll Cardiol, 76(13): 1551–1561.

Dai N, Hu Y, Tang X, et al., 2025, Cholesterol, Atherosclerotic, and Inflammatory Risks Among Patients With Statin Therapy. JACC Cardiovasc Imaging, 18(2): 242–244.

Ridker P, Everett B, Thuren T, et al., 2017, Antiinflammatory Therapy With Canakinumab for Atherosclerotic Disease. N Engl J Med, 377(12): 1119–1131.

Nidorf S, Eikelboom J, Budgeon C, et al., 2013, Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. J Am Coll Cardiol, 61(4): 404–410.

Nidorf S, Fiolet A, Mosterd A, et al., 2020, Colchicine in Patients With Chronic Coronary Disease. N Engl J Med, 383(19): 1838–1847.

Virani S, Newby L, Arnold S, et al., 2023, 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 148(9): e9–e119.

Vrints C, Andreotti F, Koskinas K C, et al., 2024, 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes: Developed by the Task Force for the Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 45(36): 3415–3537.

ICHGCP, 2025, Efficacy and Safety of Colchicine After PCI, visited on July 5, 2025, https://ichgcp.net/clinical-trials-registry/NCT06472908.

Mewton N, Roubille F, Bresson D, et al., 2021, Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 144(11): 859–869.

Ridker P, Bhatt D, Pradhan A, et al., 2023, Inflammation and Cholesterol as Predictors of Cardiovascular Events Among Patients Receiving Statin Therapy: A Collaborative Analysis of Three Randomised Trials. Lancet, 401(10384): 1293–1301.

Vaidya K, Arnott C, Martínez G, et al., 2018, Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging, 11(2 Pt 2): 305–316.

Barraclough J, Joglekar M, Januszewski A, et al., 2020, A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. J Cardiovasc Pharmacol Ther, 25(5): 444–455.

Tong D, Quinn S, Nasis A, et al., 2020, Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation, 142(20): 1890–1900.

Tardif J, Kouz S, Waters D, et al., 2019, Efficacy and Safety of Low-Dose Colchicine After Myocardial Infarction. N Engl J Med, 381(26): 2497–2505.

Yu M, Yang Y, Dong S, et al., 2024, Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial. Circulation, 150(13): 981–993.

Ho K, Tan J, 2009, Benefits and Risks of Corticosteroid Prophylaxis in Adult Cardiac Surgery: A Dose-Response Meta-Analysis. Circulation, 119(14): 1853–1866.

Kirov H, Caldonazo T, Runkel A, et al., 2024, Colchicine in Patients With Coronary Disease Who Underwent Coronary Artery Bypass Surgery: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiol, 231: 48–54.

Deftereos S, Giannopoulos G, Panagopoulou V, et al., 2014, Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart Failure: A Prospective, Randomized Study. JACC Heart Fail, 2(2): 131–137.

Pascual-Figal D, Núñez J, Pérez-Martínez M, et al., 2024, Colchicine in Acutely Decompensated Heart Failure: The COLICA Trial. European Heart Journal, 45(45): 4826–4836.

Shah B, Pillinger M, Zhong H, et al., 2020, Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial. Circ Cardiovasc Interv, 13(4): e008717.

Giannopoulos G, Angelidis C, Kouritas V, et al., 2015, Usefulness of Colchicine to Reduce Perioperative Myocardial Damage in Patients Who Underwent On-Pump Coronary Artery Bypass Grafting. Am J Cardiol, 115(10): 1376–1381.

Fu C, Wang B, 2021, Colchicine Administration for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. Am J Emerg Med, 46: 121–125.

Stewart S, Yang K, Atkins K, et al., 2020, Adverse Events During Oral Colchicine Use: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Arthritis Res Ther, 22(1): 28.

Andreis A, Imazio M, Avondo S, et al., 2021, Adverse Events of Colchicine for Cardiovascular Diseases: A Comprehensive Meta-Analysis of 14,188 Patients From 21 Randomized Controlled Trials. J Cardiovasc Med (Hagerstown), 22(8): 637–644.

Mcewan T, Robinson P, 2021, A Systematic Review of the Infectious Complications of Colchicine and the Use of Colchicine to Treat Infections. Semin Arthritis Rheum, 51(1): 101–112.

Robinson P, Terkeltaub R, Pillinger M, et al., 2022, Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. Am J Med, 135(1): 32–38.